Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia.
Mariarita SpampinatoTatiana ZuppelliIlaria DulcamareLucia LonghitanoDomenico SambataroAnnalisa SantisiAmer M AlanaziIgnazio Alberto BarbagalloNunzio VicarioRosalba ParentiAlessandra RomanoGiuseppe MusumeciGiovanni Li VoltiGiuseppe Alberto Maria PalumboFrancesco Di RaimondoAnna NicolosiSebastiano GiallongoVittorio Del FabroPublished in: Pharmaceuticals (Basel, Switzerland) (2024)
In conclusion, this study suggests that Dasatinib/Selinexor could be a promising therapeutic strategy for CML, providing new insights for new targeted therapies.
Keyphrases